ARTICLE | Company News
Cellcentric, Takeda deal
March 1, 2010 8:00 AM UTC
CellCentric granted Takeda exclusive rights to develop and commercialize an undisclosed epigenetic program. The program is in development to treat cancer. CellCentric is eligible for over $200 million...